Alzheimer's disease (AD) is the most common cause of dementia and there is currently no
cure. Novel approaches to treat AD and curb the rapidly increasing worldwide prevalence …

Platelets, the small, anucleate blood cells that originate from megakaryocytes in the bone
marrow, are typically associated with coagulation. However, it is now apparent that platelets …

The ε4 allele of the apolipoprotein E (APOE) gene, a genetic risk factor for Alzheimer's
disease, is abundantly expressed in both the brain and periphery. Here, we present …

Alzheimer's disease (AD) is the major form of dementia in the elderly population. The main
neuropathological changes in AD patients are neuronal death, synaptic alterations, brain …

Plasma transfusions are standard treatments to replace missing proteins in people with rare
genetic diseases. Prior studies have demonstrated that heterochronic parabiosis has …

Since 1906, when Dr. Alois Alzheimer first described in a patient “a peculiar severe disease
process of the cerebral cortex”, people suffering from this pathology have been waiting for a …

Alzheimer's disease (AD) is a heterogeneous neurodegenerative disorder and is the most
common cause of dementia. Furthermore, aging is considered the most critical risk factor for …

Introduction Plasma proteins affect biological processes and are common drug targets but
their role in the development of Alzheimer's disease and related dementias remains unclear …

Owing to the global exponential increase in population ageing, there is an urgent unmet
need to develop reliable strategies to slow down and delay the ageing process. Age-related …

Alzheimer's disease (AD) is the most common neurodegenerative disorder and its
prevalence is increasing. Nowadays, very few drugs effectively reduce AD symptoms and …